Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2005;54:1215-1216; doi:10.1136/gut.2005.067108
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology.

COMMENTARY

Pancreatic cancer

Silencing RNA: a novel treatment for pancreatic cancer?

N R Lemoine

Correspondence to:
Correspondence to:
Professor N Lemoine
Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1 6BQ, UK; nick.lemoine@cancer.org.uk


The high sequence specificity of RNA interference may make it suitable to treat diseases that are linked to selective or elevated expression of particular identified genes, such as in pancreatic cancer

Keywords: short interfering RNA; RNA interference; bcl-2; pancreatic cancer; apoptosis

The first 150 words of the full text of this article appear below.

The antiapoptotic gene Bcl-2 has been a target for downregulation by nucleic acid based strategies for more than a decade but the recent failure of the synthetic antisense oligonucleotide agent Genasense in phase III clinical trial caused many to think again about the worth of this approach. However, a new optimism about this and other targets is spreading through the community following several encouraging applications of the recently discovered technology of RNA interference, which is essentially a new biological version of the antisense system.1

RNA interference is considered to have begun as an evolutionarily ancient mechanism for protecting organisms from viruses. Many viruses have RNA, rather than DNA, as their genetic material and go through at least one stage in their life cycle in which they make double stranded RNA. Perhaps not surprisingly, all multicellular organisms have evolved a well conserved protein apparatus that destroys double stranded RNA . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer
M Ocker, D Neureiter, M Lueders, S Zopf, M Ganslmayer, E G Hahn, C Herold, and D Schuppan
Gut 2005 54: 1298-1308. [Abstract] [Full Text] [PDF]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs